Surgery Reduces Seizures in Drug-Resistant Epilepsy
And most common diagnoses based on resected brain specimens include hippocampal sclerosis, tumors
THURSDAY, Oct. 26, 2017 (HealthDay News) -- For pediatric patients with drug-resistant epilepsy, surgery can improve freedom from seizures, and among adults with drug-resistant focal epilepsy undergoing surgery, hippocampal sclerosis is the most common histopathological diagnosis, according to two studies published online Oct. 25 in the New England Journal of Medicine.
Rekha Dwivedi, Ph.D., from the All India Institute of Medical Sciences, and colleagues randomized 116 patients aged 18 years or younger with drug-resistant epilepsy to undergo brain surgery appropriate to the underlying cause of epilepsy plus medical therapy (57 patients) or to medical therapy alone (59 patients). The researchers found that freedom from seizures occurred in 77 and 7 percent of patients in the surgery and medical-therapy groups, respectively, at 12 months (P < 0.001).
Ingmar Blumcke, M.D., from University Hospital Erlangen in Germany, and colleagues reported diagnoses based on resected brain specimens from 9,523 patients who underwent epilepsy surgery for drug-resistant seizures. Overall, 75.9 percent of patients had onset of seizure before 18 years of age, and 75.2 percent of patients underwent surgery as adults. The researchers found that 71.9 percent of operations involved the temporal lobe. Thirty-six histopathological diagnoses in seven major disease categories were identified; the most common categories were hippocampal sclerosis (in 36.4 percent of patients [88.7 percent of cases were in adults]), tumors (in 23.6 percent), and malformations of cortical development (in 19.8 percent [52.7 percent of cases were in children]).
"The data from this large series add to the information on microscopically defined pathologic conditions in specimens obtained from surgical resection in patients with drug-resistant focal epilepsy," Blumcke and colleagues write.
Several authors from the Blumcke study disclosed ties to the biopharmaceutical industry, and one holds patents.